Early diagnosis of invasive aspergillosis in neutropenic patients. comparison between serum galactomannan and polymerase chain reaction

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 81-88

  da Silva, Rodrigo Lopes ^a   Ribeiro, Patrícia ^a   Abreu, Natacha ^a   Ferreira, Teresa ^a   Fernandes, Teresa ^a   Monteiro, Alexandra ^a   Costa, Fátima ^a   Caldas, Joana ^a   Silva, Madalena ^a   Carande, Luísa ^a   Ferreira, Gilda ^a   Conduto, António ^a   Cruz, Ernesto ^a   Sousa, Maria Henrique ^a   Rodrigues, António Silva ^a   Costa, Isabel ^a   Veiga, Joana ^a   de Sousa, Aida Botelho ^a  

^a HOSPITAL DOS CAPUCHOS   (Portugal)

Author keywords

Early diagnosis; Hematological malignancies; Intensive chemotherapy; Invasive aspergillosis (IA); Neutropenia; Serum PCR and galactomannan (GM)

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; GALACTOMANNAN; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD LEVEL; CANCER CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG MEGADOSE; EARLY DIAGNOSIS; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INTERMETHOD COMPARISON; INVASIVE ASPERGILLOSIS; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY; STANDARDIZATION;

EID: 78649351437     PISSN: None     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/cmo.s5228     Document Type: Article

References (55)

1. Penack O, Rempf P, Graf B, Blau IW, Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Annals of Oncology. 2008;19:984-9.
2. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46:327-60.
3. Patterson TF. Approaches to fungal diagnosis in transplantation. Transpl Infect Dis. 1999;1:262-72.
4. EORTC International Antimicrobial Therapy Cooperative Group. Empiric antifungal therapy in febrile granulocytopenic patients. Am J Med. 1989;86:668-72.
5. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotics and anti- fungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982;72:101-11.
6. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, et al. Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis. 2007;44:402-9.
7. Maertens J, Deeren D, Dierickx D, Theunissen K. Preemptive antifungal therapy: still a way to go. Curr Opin Infect Dis. 2006;19:551-6.
8. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41:1242-50.
9. Alexander B, Pfaller M. Contemporary tools for the diagnosis and management of invasive mycoses. Clin Infect Dis. 2006;43:15-27.
10. Ribeiro P, Costa F, Monteiro A, Caldas J, Silva M, Ferreira G, et al. Polymerase chain reaction screening for fungemia and/or invasive fungal infections in patients with hematological malignancies. Support Care Cancer. 2006;14:469-74.
11. de Pauw B, Walsh TJ, Donelly P, Stevens DA, Edwards, JE, Calandra T, et al. Revised definitions of invasive fungal disease from European Organization for Research and Treatment of Cancer/Invasive Fungal Infectious Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813-21.
12. van Burik JA, Myerson D, Schrekhise RW, Bowden RA. Panfungal PCR assay for detection of fungal infection in human blood specimens. J Clin Microb. 1998;36:1169-75.
13. Einsele H, Hebart H, Roller G, Löffler J, Rothenhofer I, Müller CA, et al. Detection and identification of fungal pathogens in blood using molecular probes. J Clin Microb. 1997;35:1353-60.
14. Herbrecht R, Letscher-Bru V, Oprea C, Lioure B, Waller J, Campos F, et al. Aspergillus Galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol. 2002;20:1898-906.
15. Musher B, Fredrick SD, Leisenring W, Balajee S, Smith C, Marr K. Aspergillus Galactomannan Enzyme Imunoassay and Quantitative PCR for Diagnosis of Invasive Aspergillosis with Bronchoalveolar Lavage Fluid. J Clin Microb. 2004;42:5517-22.
16. Scotter J, Chambers S. Comparison of Galactomannan Detection, PCR- Enzyme-Linked Immunosorbent Assay and Real-Time PCR for Diagnosis of Invasive Aspergillosis in a Neutropenic Rat Model and Effect of Caspofungin Acetate. Clinical and Diagnostic Laboratory Immunology. 2005;12:1322-7.
17. Greene RE, Schalmm HT, Oestmann JW, Stark P, Durand C, Lortholary O, et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clin Infect Dis. 2007;44:373-9.
18. Brook O, Guralnik L, Hardak E, Oren I, Sprecher H, Zuckerman T, et al. Radiological findings of early invasive pulmonary aspergillosis in immune- compromised patients. Hematol Oncol. 2009;27:102-6.
19. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis. 2002;21:161-72.
20. Tarrand JJ, Lichterfeld M, Warraich I, Luna M, Han XY, May GS, et al. Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. Am J Clin Pathol. 2003; 119:854-8.
21. Bretagne S, Marmorat-Khuong A, Kuentz M, Latgé JP, Bart-Delabesse E, Cordonnier C. Serum Aspergillus galactomannan antigen testing by sand- wich ELISA: Practical use in neutropenic patients. Journal of Infection. 1997;35:7-15.
22. Guo YL, Chen YQ, Wang K, Qin SM, Wu C, Kong JL. Accuracy of bron- choalveolar lavage galactomannan in diagnosing invasive aspergillosis: a bivariate meta-analysis and systematic review. Chest. 2010 May 7. [Epub ahead of print].
23. Danpornprasert P, Foongladda S, Tscheikuna J. Impact of bronchoalveolar lavage galactomannan on the outcome of patients at risk for invasive pulmonary aspergillosis. J Med Assoc Thai. 2010;93 Suppl 1:S86-93.
24. Bergeron A, Belle A, Sulahian A, Lacroix C, Chevret S, Raffoux E, et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest. 2010;137:410-5.
25. Maertens J, Maertens V, Theunissen K, Meersseman W, Meersseman P, Meers S, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis. 2009;49:1688-93.
26. Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis. 2008;47:674-83.
27. Anaissie EJ. Trial design for mold-active agents: time to break the mold- aspergillosis in neutropenic adults. Clin Infect Dis. 2007;44:1298-306.
28. Miceli MH, Grazziutti ML, Woods G, Zhao W, Kocoglu MH, Barlogie B, et al. Strong correlation between serum Aspergillus galactomannan index and outcome of aspergillosis in patients with haematological cancer:clinical and research implications. Clin Infect Dis. 2008;46:1412-22.
29. Maertens J, Buvé K, Theunissen K, Meersseman W, Verbeken E, Verhoef G, et al. Galactomannan serves as a surrogate endpoint for outcome of pulmonary invasive aspergillosis in neutropenic hematology patients. Cancer. 2009;115:355-62.
30. Hardak E, Yigla M, Avivi I, Fruchter O, Sprecher H, Oren I. Impact of PCR- based diagnosis of invasive pulmonary aspergillosis on clinical outcome. Bone Marrow Transplant. 2009;44:595-9.
31. Barnes RA, White PL, Bygrave C, Evans N, Healy B, Kell J. Clinical impact of enhanced diagnosis of invasive fungal disease in high-risk haematology and stem cell transplant patients. J Clin Pathol. 2009;62:64-9.
32. Lass-Florl C, Aigner J, Gunsilius E, Petzer A, Nachbaur D, Gastl G, et al. Screening for Aspergillus spp. Using polymerase chain reaction of whole blood samples from patients with haematological malignancies. Br J Haematol. 2001;113:180-4.
33. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. Clin Infect Dis. 2006;42:487-9.
34. Zhao Y, Park S, Warn P, Shrief R, Harrison E, Perlin DS. Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification. J Clin Microbiol. 2010;48:1378-83.
35. Kappe R, Rimek D. Mycoserology-did we move on? Aspergillus. Mycoses. 2010;53 Suppl 1:S26-9.
36. White PL, Bretagne S, Klingspor L, Melchers WJ, McCulloch E, Schulz B, et al. European Aspergillus PCR Initiative. Aspergillus PCR: one step closer to standardization. J Clin Microbiol. 2010;48:1231-40.
37. Klingspor L, Loeffler J. Aspergillus PCR formidable challenges and progress. Med Mycol. 2009;47 Suppl 1:S241-7.
38. Ansorg R, van den Boom R, Rath PM. Detection of Aspergillus galactomannan antigen in foods and antibiotics. Mycoses. 1997;40:353-7.
39. Adam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin-tazobactam and false positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis. 2004;38:917-20.
40. Sulahian A, Touratier S, Ribaud P. False positive test for aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med. 2003;349:2366-7.
41. Machetti M, Furfaro E, Viscoli C. Galactomannan in piperacillin-tazobactam: how much and to what extent? Antimicrob Agents Chemother. 2005;49:3984-5.
42. Mennink-Kersten MA, Ruegebrink D, Klont RR, et al. Bifidobacterial lipo- glycan as a new cause for false-positive platelia Aspergillus enzyme-linked immunosorbent assay reactivity. J Clin Microbiol. 2005;43:3925-31.
43. Giacchino M, Chiapello N, Bezzio S, et al. Aspergillus galactomannan enzyme-linked immunosorbent assay cross-reactivity caused by invasive Geotrichum capitatum. J Clin Microbiol. 2006;44:3432-4.
44. Cummings JR, Jamison GR, Boudreaux JW, Howles MJ, Walsh TJ, Hayden RT. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis. 2007;59:113-5.
45. Wheat LJ, Hackett E, Durkin M, Connolly P, Petraitiene R, Walsh TJ, et al. Histoplasmosis-associated cross-reactivity in the Bio-Rad platelia Aspergillus enzyme immunoassay. Clin Vaccine Immunol. 2007;14:638-40.
46. Asano-Mori Y, Kanda Y, Oshima K, Kako S, Shinohara A, Nakasone H, et al. False-positive Aspergillus galactomannan antigenaemia after haematopoietic stem cell transplantation. J Antimicrob Chemother. 2008;61:411-6.
47. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis. 2004;4:349-57.
48. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005;40:1762-9.
49. Marr KA, Balajee SA, McLaughlin L, Tabouret M, Bentsen C, Walsh TJ. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis. 2004;190:641-9.
50. Hsu LY, Ding Y, Phua J, Koh LP, Chan DS, Khoo KL, et al. Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect Dis. 2010;10:44.
51. Hage CA, Reynolds JM, Durkin M, Wheat LJ, Knox KS. Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoal- veolar lavage fluid. J Clin Microbiol. 2007;45:676-7.
52. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis. 2010;50:405-15.
53. Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis. 2008;47:1176-84.
54. Pazos C, Ponton J, Del Palacio A. Contribution of (1->3)-beta-D-glucan chromogenic assay to diagnosis and therapeutic monitoring of invasive aspergillosis in neutropenic adult patients: a comparison with serial screening for circulating galactomannan. J Clin Microbiol. 2005;43:299-305.
55. Sun YQ, Ji Y, Xu LP, Liu DH, Liu KY, Huang XJ. Combination of real-time polymerase chain reaction assay and serum galactomannan in the diagnosis of invasive aspergillosis in patients with hematological malignancies and recipients of hematopoietic stem cell transplantation. Zhonghua Yi Xue Za Zhi. 2010;90:375-8.